We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 184

Court finds claims do not cover method of medical treatment, orders that they issue

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 19 2015

In this decision, AbbVie brought a judicial review of a decision of the Commissioner of Patents refusing to issue its patent. The issue was whether

Minister’s decision to grant NOA to generic company set aside, as the generic did not comply with the NOC regulations

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 19 2015

In this proceeding, Pfizer sought to judicially review the Minister of Health’s decision to grant Teva a NOC for exemestane. A company called GMP

Court refused to grant protective order covering NOA

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 19 2015

In the context of a proceeding brought pursuant to the NOC Regulations, Mylan sought a confidentiality that would allow it to designate portions of

Antibody patent found valid and infringed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 27 2014

The Court recently decided a patent infringement case dealing with antibodies. The claims at issue in AbbVie’s patent relate to the use of a human

Reply affidavits allowed when new documents introduced in responding evidence

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 9 2014

In this case, there is a partial reversal of evidence. Apotex brought a motion for leave to file reply evidence. Allergan did not oppose parts of the

Motion for additional rebuttal witnesses in re-opened trial denied

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • November 28 2011

The Defendants brought a motion seeking to call rebuttal witnesses in a trial that has been re-opened to allow evidence that may contradict the evidence given at trial

Failure to produce evidence of development leads to adverse inference on obviousness

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 9 2014

These proceedings, brought pursuant to the NOC Regulations, dealt with two patents. One set of reasons was issued. The application was granted in

Court of Appeal upholds decision relating to sildenafil use patent

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • January 27 2014

Pfizer Ireland Pharmaceuticals v. Apotex Inc., 2014 FCA 13 Drug: VIAGRA sildenafil In Apotex' action for impeachment of the Pfizer patent

Pleadings amendments refused on the eve of trial

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • February 7 2011

BMS brought a motion to strike out certain amendments made to its pleadings by Apotex

Appeal of listing of drug on register of innovative drugs dismissed

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • June 6 2011

This was an appeal of the decision of a Prothonotary to strike the application of the Canadian Generic Pharmaceutical Association (CGPA) for judicial review of the addition of AVAMYS to Health Canada’s Register of Innovative Drugs (the Register